natgillin/translations-raw huggingface dataset:
Zinforo må heller ikke anvendes hos patienter, der er overfølsomme for andre antibiotika af cefalosporin-typen, eller hos patienter med svær allergi over for andre betalactam-antibiotika.
Zinforo must also not be used in patients who are hypersensitive to other antibiotics belonging to the cephalosporin class and those who are severely allergic to other beta- lactam antibiotics.
Zinforo må ikke anvendes hos personer, der er overfølsomme (allergiske) over for ceftarolin fosamil eller andre af indholdsstofferne.
Zinforo must not be used in people who are hypersensitive (allergic) to ceftaroline fosamil or any of the other ingredients.
Zinforo må ikke anvendes til børn i alderen under 2 måneder, da der ikke foreligger tilstrækkelige data for disse patientgrupper.
Zinforo should not be used in children below the age of 2 months as not enough data exist in these populations.
Zinforo pulver skal rekonstitueres med 20 ml sterilt vand til injektion.
Zinforo powder should be reconstituted with 20 ml of sterile water for injections.
Zinforo var ligeså effektivt som andre antibiotiske midler til behandling af infektioner i både hud og underliggende væv og til behandling af lungebetændelse hos voksne :
Zinforo was as effective as the other antibiotics in treating both skin and soft tissue infections and pneumonia in adults:
Zinforo virker ved at dræbe bestemte bakterier, som kan forårsage alvorlige infektioner.
Zinforo works by killing certain bacteria, which can cause serious infections.
Zink har været anvendt til at behandle Wilsons’ sygdom siden 1958.
Zinc has been used to treat Wilson’s disease since 1958.
Zinkchlorid Glycerol Metacresol
Zinc chloride Glycerol Metacresol
Zinkchlorid Glycerol Metacresol Phenol
Zinc chloride Glycerol Metacresol Phenol
Zinkchlorid Metacresol Glycerol
Zinc chloride Metacresol Glycerol
Zinkchlorid Natriumchlorid Methylparahydroxybenzoat Natriumacetat
Zinc chloride Sodium chloride
Zinkchlorid Zinkacetat Natriumchlorid
Zinc chloride Zinc acetate Sodium chloride
zinkchlorid, glycerol, metacresol, dinatriumphosphatdihydrat, natriumhydroxid, saltsyre og vand til injektionsvæsker
zinc chloride, glycerol, metacresol, disodium phosphate dihydrate, sodium hydroxide, hydrochloric acid and water for injections.
zinkchlorid, glycerol, metacresol, phenol, dinatriumphosphatdihydrat, natriumhydroxid/saltsyre til pH- justering, protaminsulfat og vand til injektionsvæsker
zinc chloride, glycerol, metacresol, phenol, disodium phosphate dihydrate, sodium hydroxide/hydrochloric acid for pH adjustment, protamine sulfate and water for injections
Zinkchlorid, metacresol, glycerol, saltsyre / natriumhydroxid (til pH-justering), vand til injektionsvæsker
Zinc chloride, metacresol, glycerol, hydrochloric acid / sodium hydroxide (for pH adjustment), water for injections
zinkchlorid, natriumchlorid, methylparahydroxybenzoat, natriumacetat, natriumhydroxid, saltsyre og vand til injektionsvæsker
zinc chloride, sodium chloride, methyl parahydroxybenzoate, sodium acetate, sodium hydroxide, hydrochloric acid and water for injections
zinkchlorid, zinkacetat, natriumchlorid, methylparahydroxybenzoat, natriumacetat, natriumhydroxid, saltsyre og vand til injektionsvæsker
zinc chloride, zinc acetate, sodium chloride, methyl parahydroxybenzoate, sodium acetate, sodium hydroxide, hydrochloric acid and water for injections
Zinkoxid 0,088 mg
Zinc oxide 0.088 mg
Zinkoxid Metacresol glycerol saltsyre (til pH-justering) natriumhydroxid (til pH-justering) vand til injektionsvæsker
Zinc oxide Metacresol glycerol hydrochloric acid (for pH adjustment) sodium hydroxide (for pH adjustment) water for injections
Zinkstearat
Zinc stearate
Zoals elk geneesmiddel kan ook dit geneesmiddel bijwerkingen hebben, al krijgt niet iedereen daarmee te maken.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Zoely er et lægemiddel, der fås som 24 hvide "aktive" tabletter, der indeholder de aktive stoffer nomegestrolacetat (2,5 mg) og estradiol (1,5 mg), og fire gule "inaktive" tabletter (placebo), som ikke indeholder noget aktivt stof.
Zoely is a medicine available as 24 white ‘active’ tablets that contain the active substances nomegestrol acetate (2.5 mg) and estradiol (1.5 mg), and four yellow ‘inactive’ (placebo) tablets that do not contain any active substance.
Zoely er ikke indiceret under graviditet.
Zoely is not indicated during pregnancy.
Zoely kan også påvirke funktionen af anden medicin - såsom det anti-epileptiske lægemiddel lamotrigin.
Zoely may also interfere with the working of other medicines – such as the anti-epileptic lamotrigine.
Zoely påvirker ikke eller kun i ubetydelig grad din evne til at køre bil og betjene maskiner.
Zoely has no or negligible effect on your ability to drive and use machines.
Zoely virker ved at
Zoely works by changing
Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIEN
Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM
Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIEN
Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la Neuve BELGIUM
Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIEN
Zoetis Belgium SA Rue Laid Burniat, 1 1348 Louvain-la-Neuve BELGIUM
Zoetis Belgium SA Zoetis Lietuva UAB
Zoetis Belgium SA
Zoetis Belgium SA, Rue Laid Burniat, 1, 1348 Louvain-la-Neuve, BELGIEN
Zoetis Belgium SA, Rue Laid Burniat 1, 1348 Louvain-la-Neuve, BELGIUM
Zoetis Netherlands HoldingsBV Tel: +385 1 644 1460
Zoetis Netherlands Holdings BV Tel: +385 1 644 1460
Zoledonsyre medac må ikke blandes med calcium eller anden divalent kationholdig infusionsopløsning, såsom Ringers lactatopløsning, og bør administreres som en enkelt intravenøs opløsning i en separat infusionsslange.
Zoledronic acid medac must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
zoledro n-syre
zoledroni c acid
Zoledron- syre
Placeb o
zoledron- syre
zoledroni c acid
Zoledron- syre
Zoledronic acid
Zoledron- syre (%)
Zoledronic acid (%)
Zoledron- syre 4 mg
zoledronic acid 4 mg
Zoledronic acid Actavis er et "generisk lægemiddel".
Zoledronic acid Actavis is a ‘generic medicine’.
Zoledronic Acid Hospira er et “generisk” og ”hybridt” lægemiddel.
Zoledronic Acid Hospira is a ‘generic’ and a ‘hybrid’ medicine.
Zoledronic acid Teva Pharma anvendes også til at behandle Pagets knoglesygdom hos voksne.
Zoledronic acid Teva Pharma is also used to treat Paget’s disease of the bone in adults.
Zoledronic acid Teva Pharma er et ”generisk lægemiddel”.
Zoledronic acid Teva Pharma is a ‘generic medicine’.
Zoledrons yre (%)
Zoledronic acid (%)
Zoledronsy re (N=1.065) hændelses- rate (%)
Zoledronic acid (N = 1,065) event rate (%)
Zoledronsy re (N=1.065) hændelses- rate (%)
Zoledronic acid (N=1,065) event rate (%)
Zoledronsy re (N=3.875) hændelses- rate (%)
Zoledronic acid (N=3,875) event rate (%)
Zoledronsyre
medac Zoledronic acid
Zoledronsyre 4 mg
zoledronic acid 4 mg
Zoledronsyre 4 mg blev også undersøgt i et dobbeltblindt, randomiseret, placebokontrolleret studie hos 228 patienter med dokumenterede knoglemetastaser fra brystkræft, for at evaluere virkningen af zoledronsyre 4 mg på ratioen for forekomst af skeletrelaterede hændelser (SRE) beregnet som det totale antal af SRE’er (eksklusiv hyperkalcæmi og justeret for tidligere frakturer) delt med den totale risikoperiode.
Zoledronic acid 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of zoledronic acid 4 mg on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period.
Zoledronsyre 4 mg blev også undersøgt i et dobbeltblindt, randomiseret, placebokontrolleret studie i 228 patienter med dokumenterede knoglemetastaser fra brystkræft, for at evaluere effekten af 4 mg zoledronsyre på skeletrelaterede hændelser (SRE) forekomsts-ratio beregnet som det totale antal af SRE hændelser (eksklusiv hypercalcæmi og justeret for tidligere frakturer) delt med den totale risikoperiode.
Zoledronic acid 4 mg was also studied in a double-blind, randomised, placebo-controlled trial in 228 patients with documented bone metastases from breast cancer to evaluate the effect of 4 mg zoledronic acid on the skeletal related event (SRE) rate ratio, calculated as the total number of SRE events (excluding hypercalcaemia and adjusted for prior fracture), divided by the total risk period.
Zoledronsyre 4 mg reducerede risikoen for SRE med 41 % i en analyse med multiple hændelser (risikoforhold=0,59, p=0,019) sammenlignet med placebo.
Zoledronic acid 4 mg reduced the risk of SREs by 41 % in a multiple event analysis (risk ratio=0.59, p=0.019) compared with placebo.
Zoledronsyre 4 mg reducerede signifikant andelen af patienter, der oplevede mindst én skeletrelateret hændelse (SRE), forsinkede mediantiden til første SRE med >5 måneder og reducerede den årlige incidens af hændelser pr. patient - skeletal morbiditet.
Zoledronic acid 4 mg significantly reduced the proportion of patients experiencing at least one skeletal related event (SRE), delayed the median time to first SRE by > 5 months, and reduced the annual incidence of events per patient – skeletal morbidity rate.
Zoledronsyre Accord 4 mg/5 ml koncentrat til infusionsvæske, opløsning
Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion
Zoledronsyre Accord 4 mg/5 ml koncentrat til infusionsvæske, opløsning zoledronsyre
Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Zoledronsyre Accord 4 mg/5 ml sterilt koncentrat zoledronsyre
Zoledronic Acid Accord 4 mg/5 ml sterile concentrate Zoledronic acid
Zoledronsyre Accord bør ikke bruges til børn og teenagere under 18 år.
Zoledronic Acid Accord is not recommended for use in adolescents and children below the age of 18 years.
Zoledronsyre Accord er et "generisk lægemiddel".
Zoledronic Acid Accord is a ‘generic medicine’.
Zoledronsyre Accord er et lægemiddel, der indeholder det aktive stof zoledronsyre.
Zoledronic Acid Accord is a medicine that contains the active substance zoledronic acid.
Zoledronsyre Accord gives som drop (infusion) i en vene.
Zoledronic Acid Accord is given as a drip (infusion) into a vein which should take at least
Zoledronsyre Accord indeholder natrium
Zoledronic Acid Accord contains sodium.
Zoledronsyre Accord kan også anvendes til at behandle forhøjet calciumindhold i blodet, der skyldes svulster (tumorer).
Zoledronic Acid Accord can also be used to treat the hypercalcaemia caused by tumours.
Zoledronsyre Accord leveres flydende koncentrat i et hætteglas.
Zoledronic Acid Accord is supplied as a liquid concentrate in a vial.
Zoledronsyre Accord må kun gives af sundhedspersonale, som er trænet til at indgive bisfosfonater intravenøst, dvs. gennem en blodåre.
Zoledronic Acid Accord must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronsyre Accord må kun udskrives og administreres til patienter af sundhedspersonale med erfaring i administration af intravenøse bisfosfonater.
Zoledronic Acid Accord must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates.
Zoledronsyre Accord opbevares utilgængeligt for børn.
Keep Zoledronic Acid Accord out of the reach and sight of children.
Zoledronsyre Accord udleveres kun efter recept og må kun udskrives og gives af en sundhedsperson med erfaring i anvendelse af denne type lægemiddel, som indgives i en vene.
Zoledronic Acid Accord can only be obtained with a prescription and must only be prescribed and given by a healthcare professional who has experience in the use of this type of medicine given into a vein.
Zoledronsyre Accord-koncentrat må ikke blandes med calcium eller anden divalent kationholdig infusionsopløsning såsom Ringer-lactatopløsning, og bør indgives som en enkelt intravenøs opløsning i en separat infusionsslange.
Zoledronic Acid Accord concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Zoledronsyre Accord-koncentrat må ikke blandes med calciumholdige opløsninger eller andre opløsninger indeholdende divalente kationer som lakteret Ringers væske.
Do not mix Zoledronic Acid Accord concentrate with calcium-containing or other divalent cation-containing solutions such as lactated Ringer’s solution.
Zoledronsyre Actavis 4 mg/5 ml koncetrat til infusionsvæske, opløsning, leveres som pakninger indeholdende 1, 4 eller 10 hætteglas.
Zoledronic acid Actavis 4 mg/5 ml concentrate for solution for infusion is supplied as packs containing 1, 4 or 10 vials.
Zoledronsyre Actavis gives som drop (infusion) i en vene.
Zoledronic acid Actavis is given as a drip (infusion) into a vein which should take at least
Zoledronsyre Actavis koncentrat må ikke blandes med calcium eller anden divalent kationholdig infusionsopløsning såsom Ringer-lactatopløsning, og bør indgives som en enkelt intravenøs opløsning i en separat infusionsslange.
Zoledronic acid Actavis must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer’s solution, and should be administered as a single intravenous solution in a separate infusion line.
Zoledronsyre Actavis må kun gives af sundhedspersonale, som er trænet til at indgive bisfosfonater intravenøst, dvs. gennem en blodåre.
Zoledronic acid Actavis must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronsyre bindes ikke mærkbart til plasmaproteiner (cirka 43-55% bundet), og interaktioner med stærkt proteinbundende stoffer på grund af fortrængning, er derfor usandsynlig.
Zoledronic acid is not highly bound to plasma proteins (approximately 43-55% bound) and interactions resulting from displacement of highly protein-bound drugs are therefore unlikely.
Zoledronsyre blev undersøgt hos mænd og kvinder i alderen over 30 år med primært mild til moderat Pagets sygdom af knoglerne (gennemsnitlig serum alkalisk fosfatase niveau på 2,6-3,0 gange den øvre grænseværdi for det normale aldersspecifikke referenceområde ved inklusion i studiet) bekræftet ved radiografisk påvisning.
Zoledronic acid was studied in male and female patients aged above 30 years with primarily mild to moderate Paget's disease of the bone (median serum alkaline phosphatase level 2.6–3.0 times the upper limit of the age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.
Zoledronsyre blev undersøgt hos mænd og kvinder i alderen over 30 år med primært mild til moderat Pagets sygdom af knoglerne (gennemsnitlig serum alkalisk fosfatase niveau på 2,6-3,0 gange den øvre grænseværdi for det normale aldersspecifikke referenceområde ved inklusion i studiet) bekræftet ved radiografisk påvisning.
Zoledronic acid was studied in male and female patients aged above 30 years with primarily mild to moderate Paget’s disease of the bone (median serum alkaline phosphatase level 2.6-3.0 times the upper limit of the age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.
Zoledronsyre bruges også til patienter, der for nylig har brækket deres hofte ved et mindre uheld, fx ved fald, og som derfor har risiko for yderligere knoglebrud.
Zoledronic acid Teva Pharma is also used in patients who have recently broken their hip in a minor trauma such as a fall and therefore are at risk of subsequent bone breaks.
Zoledronsyre bør anvendes med forsigtighed, når det anvendes samtidigt med andre lægemidler, som kan påvirke nyrefunktionen (se pkt.
Zoledronic acid should be used with caution when concomitantly used with other medicinal products that could impact renal function (see section 4.5).
Zoledronsyre bør kun genoptages, når serum-kreatinin igen er inden for 10 % af baseline.
Zoledronic acid should only be resumed when serum creatinine returns to within 10% of baseline.
Zoledronsyre Hospira 4 mg/100 ml infusionsvæske, opløsning
Zoledronic Acid Hospira 4 mg/100 ml solution for infusion
Zoledronsyre Hospira 4 mg/100 ml infusionsvæske, opløsning indeholder 4 mg zoledronsyre i 100 ml infusionsvæske, opløsning, som er klar til brug til patienter med normal nyrefunktion.
Zoledronic Acid Hospira 4 mg/100 ml solution for infusion contains 4 mg zoledronic acid in 100 ml of infusion solution for immediate use in patients with normal renal function.
Zoledronsyre Hospira 4 mg/5 ml koncentrat til infusionsvæske, opløsning
Zoledronic Acid Hospira 4 mg/5 ml concentrate for solution for infusion
Zoledronsyre Hospira 4 mg/5 ml sterilt koncentrat I.V.
Zoledronic Acid Hospira 4 mg/5 ml Sterile concentrate IV
Zoledronsyre Hospira 5 mg/100 ml infusionsopløsning indeholder:
What Zoledronic Acid Hospira 5 mg/100 ml solution for infusion contains
Zoledronsyre Hospira bør ikke bruges til børn og unge under 18 år.
Zoledronic Acid Hospira is not recommended for use in adolescents and children below the age of 18 years.
Zoledronsyre Hospira er en klar, farveløs opløsning.
Zoledronic Acid Hospira is a clear and colourless solution.
Zoledronsyre Hospira er klar til brug.
Zoledronic Acid Hospira is ready for use.
Zoledronsyre Hospira er kontraindiceret under amning (se pkt.
Zoledronic Acid Hospira is contraindicated during breast-feeding (see section 4.3).
Zoledronsyre Hospira er kontraindiceret under gravididitet (se pkt.4.3).
Zoledronic Acid Hospira is contraindicated during pregnancy (see section 4.3).
Zoledronsyre Hospira har ingen eller kun ubetydelig indvirkning på evnen til at køre bil og betjene maskiner.
Zoledronic Acid Hospira has no or negligible influence on the ability to drive and use machines.
Zoledronsyre Hospira kan gives til patienter i alderen 65 år og derover.
Zoledronic Acid Hospira for infusion can be given to people aged 65 years and over.
Zoledronsyre Hospira kan også give andre bivirkninger
Zoledronic Acid Hospira may also cause other side effects
Zoledronsyre Hospira leveres som flydende koncentrat (koncentrat til infusionsvæske, opløsning eller sterilt koncentrat) i et hætteglas.
Zoledronic Acid Hospira is supplied as a liquid concentrate (referred to as a ‘concentrate for solution for infusion’ or ‘sterile concentrate’) in a vial.
Zoledronsyre Hospira må ikke blandes med calcium eller anden divalent kationholdig infusionsopløsning såsom Ringer’s laktatopløsning, og bør indgives som en enkelt intravenøs opløsning i en separat infusionsslange.
Zoledronic Acid Hospira must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line.
Zoledronsyre Hospira må kun gives af sundhedspersonale, som er trænet til at indgive bisfosfonater intravenøst, dvs. gennem en blodåre (også kaldt IV administration).
Zoledronic Acid Hospira must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein (also referred to as ‘IV’ administration).
Zoledronsyre Hospira må kun gives af sundhedspersonale, som er trænet til at indgive bisfosfonater intravenøst, dvs. gennem en blodåre.
Zoledronic Acid Hospira must only be given by healthcare professionals trained in administering bisphosphonates intravenously, i.e. through a vein.
Zoledronsyre Hospira opløsning må ikke blandes med calciumholdige eller andre divalente kationholdige opløsninger som Ringer’s laktatopløsning.
Do not mix Zoledronic Acid Hospira concentrate with calcium-containing or other divalent cation containing solutions such as lactated Ringer’s solution.
Zoledronsyre Hospira påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj eller betjene maskiner.
Zoledronic Acid Hospira has no or negligible influence on the ability to drive and use machines.
Zoledronsyre inhiberer ikke humane P450-enzymer in vitro og udviser ingen biotransformation, og i dyreforsøg blev <3 % af den administrerede dosis genfundet i fæces, hvilket antyder, at leverfunktionen ikke spiller en væsentlig rolle for zoledronsyres farmakokinetiske egenskaber.
Zoledronic acid does not inhibit human P450 enzymes in vitro, shows no biotransformation and in animal studies < 3 % of the administered dose was recovered in the faeces, suggesting no relevant role of liver function in the pharmacokinetics of zoledronic acid.
Zoledronsyre medac 4 mg/100 ml infusionsvæske, opløsning
Zoledronic acid medac 4 mg/100 ml solution for infusion
Zoledronsyre medac 4 mg/100 ml infusionsvæske, opløsning
Zoledronic acid medac 4mg/100ml solution for infusion
Zoledronsyre medac 4 mg/100 ml infusionsvæske, opløsning Zoledronsyre
Zoledronic acid medac 4 mg/100 ml solution for infusion Zoledronic acid
Zoledronsyre medac 4 mg/100 ml infusionsvæske, opløsning, indeholder 4 mg zoledronsyre i 100 ml infusionsvæske, opløsning, som er klar til brug hos patienter med normal nyrefunktion.
Zoledronic acid medac 4 mg/100 ml solution for infusion contains 4 mg zoledronic acid in 100 ml of infusion solution for immediate use in patients with normal renal function.
Zoledronsyre medac 4 mg/100 ml infusionsvæske, opløsning, kan anvendes straks uden yderligere tilberedning til patienter med normal nyrefunktion.
Zoledronic acid medac 4 mg/100 ml solution for infusion can be used immediately without further preparation for patients with normal renal function.
Zoledronsyre medac 4 mg/5 ml koncentrat til infusionsvæske, opløsning
Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion
Zoledronsyre medac 4 mg/5 ml koncentrat til infusionsvæske, opløsning
Zoledronic acid medac 4mg/5ml concentrate for solution for infusion
Zoledronsyre medac 4 mg/5 ml koncentrat til infusionsvæske, opløsning Zoledronsyre
Zoledronic acid medac 4 mg/5 ml concentrate for solution for infusion Zoledronic acid
Zoledronsyre medac administreres som drop (infusion) i en vene.
Zoledronic acid medac is given as a drip (infusion) into a vein which should take at least
Zoledronsyre medac bør ikke bruges til børn og unge under 18 år.
Zoledronic acid medac is not recommended for use in adolescents and children below the age of 18 years.
Zoledronsyre medac gives som drop (infusion) i en vene.
Zoledronic acid medac is given as a drip (infusion) into a vein which should take at least
Zoledronsyre medac koncentrat må ikke blandes med calciumholdige opløsninger eller andre opløsninger, der indeholder divalente kationer såsom lakteret Ringers væske.
Do not mix Zoledronic acid medac concentrate with calcium-containing or other divalent cation containing solutions such as lactated Ringer’s solution.
Zoledronsyre medac koncentrat må ikke blandes med calciumholdige opløsninger eller andre opløsninger, der indeholder divalente kationer såsom lakteret Ringers væske.
Do not mix Zoledronic acid medac with calcium-containing or other divalent cation containing solutions such as lactated Ringer’s solution.
Zoledronsyre medac leveres i enkeltpakninger, som indeholder 1 hætteglas eller 4 hætteglas, og multipakninger med 4 eller 10 pakninger, der hver indeholder 1 hætteglas.
Zoledronic acid medac is supplied as unit packs containing 1 vial or 4 vials and as multipacks of 4 or 10 packs each containing 1 vial.
Zoledronsyre medac leveres som enkeltpakninger, der indeholder 1 hætteglas eller 4 hætteglas, og som multipakninger med 4 eller 10 pakninger, der hver indeholder 1 hætteglas.
Zoledronic acid medac is supplied as unit packs containing 1 vial or 4 vials and as multipacks of 4 or 10 packs each containing 1 vial.
Zoledronsyre medac leveres som infusionsvæske, opløsning, i 100 ml farveløs glasflaske (type 1) med gummipropper (halobutyl, overtrukne med fluorpolymer) og ”flip-off” låg af aluminium.
Zoledronic acid medac is supplied as solution for infusion in a 100 ml colourless glass bottle (type I) with rubber stoppers (halobutyl, fluoropolymer coated) and aluminium flip-off caps.